126 related articles for article (PubMed ID: 8172792)
1. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Osborne CK; Sunderland MC; Neidhart JA; Ravdin PM; Abeloff MD
Ann Oncol; 1994 Jan; 5(1):43-7. PubMed ID: 8172792
[TBL] [Abstract][Full Text] [Related]
2. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
Ardizzoni A; Venturini M; Sertoli MR; Giannessi PG; Brema F; Danova M; Testore F; Mariani GL; Pennucci MC; Queirolo P
Br J Cancer; 1994 Feb; 69(2):385-91. PubMed ID: 8297739
[TBL] [Abstract][Full Text] [Related]
9. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
[TBL] [Abstract][Full Text] [Related]
10. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Partyka S; Dumas P; Ajani J
Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
15. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Scinto AF; Ferraresi V; Campioni N; Tonachella R; Piarulli L; Sacchi I; Giannarelli D; Cognetti F
Ann Oncol; 1995 Sep; 6(7):665-71. PubMed ID: 8664187
[TBL] [Abstract][Full Text] [Related]
16. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
[TBL] [Abstract][Full Text] [Related]
18. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
Hoekman K; Wagstaff J; van Groeningen CJ; Vermorken JB; Boven E; Pinedo HM
J Natl Cancer Inst; 1991 Nov; 83(21):1546-53. PubMed ID: 1960751
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
Steward WP; Scarffe JH; Dirix LY; Chang J; Radford JA; Bonnem E; Crowther D
Br J Cancer; 1990 May; 61(5):749-54. PubMed ID: 1692472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]